Juergen Mestan

822 total citations
11 papers, 667 citations indexed

About

Juergen Mestan is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Juergen Mestan has authored 11 papers receiving a total of 667 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Hematology and 3 papers in Genetics. Recurrent topics in Juergen Mestan's work include Chronic Myeloid Leukemia Treatments (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Eosinophilic Disorders and Syndromes (3 papers). Juergen Mestan is often cited by papers focused on Chronic Myeloid Leukemia Treatments (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Eosinophilic Disorders and Syndromes (3 papers). Juergen Mestan collaborates with scholars based in Switzerland, United States and Germany. Juergen Mestan's co-authors include Francesco Hofmann, Doriano Fabbro, Mark Pearson, Diana Graus Porta, Hans‐Georg Capraro, Carlos Garcı́a-Echeverrı́a, Georg Martiny‐Baron, Robert Cozens, Stephan Ruetz and Josef Brueggen and has published in prestigious journals such as Blood, Cancer Cell and Cancer Research.

In The Last Decade

Juergen Mestan

10 papers receiving 651 citations

Peers

Juergen Mestan

MB

EDM

ONCOL

CR

HEMAT

Adrian Zumsteg Switzerland

Ann Thor United States

Diana Zambelli Italy

Terry Lipari United States

Henry Koo United States

Jesse McGreivy United States

Cristina Bilbao Spain

W. M. Linehan United States

Annunciata Romano Italy

Jung Hun Song South Korea

Adrian Zumsteg Switzerland

Juergen Mestan

287 ×0.7

MB

76 ×0.3

EDM

271 ×1.5

ONCOL

89 ×0.6

CR

48 ×0.5

HEMAT

Citations per year, relative to Juergen Mestan Juergen Mestan (= 1×) peers Adrian Zumsteg

Countries citing papers authored by Juergen Mestan

Since Specialization

Citations

This map shows the geographic impact of Juergen Mestan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juergen Mestan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juergen Mestan more than expected).

Fields of papers citing papers by Juergen Mestan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juergen Mestan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juergen Mestan. The network helps show where Juergen Mestan may publish in the future.

Co-authorship network of co-authors of Juergen Mestan

This figure shows the co-authorship network connecting the top 25 collaborators of Juergen Mestan. A scholar is included among the top collaborators of Juergen Mestan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juergen Mestan. Juergen Mestan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Weisberg, Ellen, Laurie Catley, Renee D. Wright, et al.. (2016). Beneficial Effects of Combining Nilotinib and Imatinib in Preclinical Models of BCR/ABL+ Leukemias Nilotinib and Imatinib Against Bcr-Abl+ Leukemia.

2.

Cmiljanović, Vladimir, Robert A. Ettlin, Florent Beaufils, et al.. (2015). Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability. Cancer Research. 75(15_Supplement). 4514–4514. 3 indexed citations

3.

Growney, Joseph D., Fang Li, Shumei Qiu, et al.. (2013). Abstract 1620: Dovitinib has anti-tumor activity in gastrointestinal stromal tumor (GIST) cell lines.. Cancer Research. 73(8_Supplement). 1620–1620. 1 indexed citations

4.

Kyriakakis, Emmanouil, Marco Cavallari, Dennis Pfaff, et al.. (2011). IL-8-mediated angiogenic responses of endothelial cells to lipid antigen activation of iNKT cells depend on EGFR transactivation. Journal of Leukocyte Biology. 90(5). 929–939. 17 indexed citations

5.

Kawahara, Ei, Tsuyoshi Miyake, Ichiro Umemura, et al.. (2008). Discovery of potent and selective focal adhesion kinase inhibitors. 1 indexed citations

6.

Weisberg, Ellen, Laurie Catley, Renee D. Wright, et al.. (2006). Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 109(5). 2112–2120. 79 indexed citations

7.

Bubnoff, Nikolas von, et al.. (2005). Bcr-Abl Resistance Screening Predicts a Limited Spectrum of Point Mutations To Be Associated with Clinical Resistance to the Abl Kinase Inhibitor AMN107.. Blood. 106(11). 1983–1983. 1 indexed citations

8.

Manley, Paul W., Juergen Mestan, Thomas Meyer, & Doriano Fabbro. (2004). An ELISA for PDGFR phosphorylation: Comparison of effects of STI571 on cellular Bcr-Abl, c-Kit and PDGFR-β protein kinases. Cancer Research. 64. 345–346. 1 indexed citations

9.

Wagner, Klaus W., Lisa M. Sapinoso, Wael El‐Rifai, et al.. (2004). Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene. 23(39). 6621–6629. 114 indexed citations

10.

Garcı́a-Echeverrı́a, Carlos, Mark Pearson, Andreas Marti, et al.. (2004). In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 5(3). 231–239. 447 indexed citations

11.

Mestan, Juergen, et al.. (2004). AMN107: In Vitro Profile of a New Inhibitor of the Tyrosine Kinase Activity of Bcr-Abl.. Blood. 104(11). 1978–1978. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact